New hope for rare skin disease: first human trial of BCX17725 begins
Disease control
Recruiting now
This early-stage study tests a new drug called BCX17725 for Netherton syndrome, a rare genetic condition that causes severe skin redness and scaling. The trial first checks safety in healthy adults, then tests the drug in people with the condition to see if it improves skin sympt…
Phase: PHASE1 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 04:43 UTC